Blanca Díaz Benito

Ms. Blanca Díaz Benito

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2025 in Stroke
Verified
Journal Article
Open access
GDGaohong Di
Gaohong Di
SVSandra Vázquez-Reyes
Sandra Vázquez-Reyes
BBBlanca Díaz Benito
Blanca Díaz Benito
CPCarolina Peña-Martinez
Carolina Peña-Martinez
AGAlicia García-Culebras
Alicia García-Culebras
ILIgnacio Lizasoain
Ignacio Lizasoain
BACKGROUND: Acute ischemic stroke treatment typically involves tissue-type plasminogen activator (tPA) or tenecteplase, but about 50% of patients do not achieve successful reperfusion. The causes of tPA resistance, influenced by thrombus composition and timing, are not fully clear. Neutrophil extracellular traps (NETs), associated with poor outcomes and reperfusion resistance, contribute to thrombosis. DNase-I, which degrades neutrophil extracellular traps, could improve thrombolytic efficacy. However, more studies are needed to understand the impact of DNase-I in tPA-sensitive stroke models, the safety of coadministering DNase-I and tPA regarding hemorrhagic transformation (HT), optimal timing for use, and effects on aspirin-treated animals. METHODS: We used in situ thromboembolic stroke, a tPA-sensitive model, where late tPA administration causes HT. Middle cerebral artery occlusion was induced at different zeitgeber times (ZT) to study the optimal timing for administration. DNase-I, tPA, and aspirin were administered at various times to evaluate their effects. RESULTS: DNase-I reduced infarct volume and improved functional outcomes 24 hours post-middle cerebral artery occlusion by decreasing plasma and cortical neutrophil extracellular trap levels. DNase-I caused no bleeding or impact on HT induced by late tPA. Its protective effect was only seen when given during the daytime (rodent inactive phase; ZT4–7), not overnight (active phase; ZT13–16). Chronic aspirin pretreatment increased tPA-induced HT but did not change the protective effects of DNase-I, with or without tPA. CONCLUSIONS: Our study demonstrates that daytime (inactive phase) DNase-I administration is a safe and effective treatment for experimental stroke. This is particularly important given the 2 ongoing clinical trials for stroke patients. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05203224 and NCT05880524.

6 December 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
CGCristina Granados-Martinez
Cristina Granados-Martinez
NANuria Alfageme-Lopez
Nuria Alfageme-Lopez
MOManuel Navarro Oviedo
Manuel Navarro Oviedo
CNCarmen Nieto-Vaquero
Carmen Nieto-Vaquero
MCMaría Isabel Cuartero
María Isabel Cuartero
JPJesus Miguel Pradillo
Jesus Miguel Pradillo
Stroke is one of the most devastating pathologies in terms of mortality, cause of dementia, major adult disability, and socioeconomic burden worldwide. Despite its severity, treatment options remain limited, with no pharmacological therapies available for hemorrhagic stroke (HS) and only fibrinolytic therapy or mechanical thrombectomy for ischemic stroke (IS). In the pathophysiology of stroke, after the acute phase, many patients develop systemic immunosuppression, which, combined with neurological dysfunction and hospital management, leads to the onset of stroke-associated infections (SAIs). These infections worsen prognosis and increase mortality. Recent evidence, particularly from experimental studies, has highlighted alterations in the microbiota–gut–brain axis (MGBA) following stroke, which ultimately disrupts the gut flora and increases intestinal permeability. These changes can result in bacterial translocation (BT) from the gut to sterile organs, further contributing to the development of SAIs. Given the novelty and significance of these processes, especially the role of BT in the development of SAIs, this review summarizes the latest advances in understanding these phenomena and discusses potential therapeutic strategies to mitigate them, ultimately reducing post-stroke complications and improving treatment outcomes.

16 January 2026 in Circulation Research
Verified
Journal Article
Open access
SVSandra Vázquez-Reyes
Sandra Vázquez-Reyes
AGAlicia García-Culebras
Alicia García-Culebras
GDGaohong Di
Gaohong Di
FCFrancisco J. De Castro-Millán
Francisco J. De Castro-Millán
BBBlanca Díaz Benito
Blanca Díaz Benito
MMMaría Ángeles Moro
María Ángeles Moro
BACKGROUND: Stroke remains a leading cause of mortality and disability, driven by complex, time-dependent mechanisms that aggravate ischemic injury. Collateral perfusion dictates infarct size, expansion rate, and penumbral preservation, yet its regulation is poorly understood. Beyond structural/genetic factors such as aging or cardiovascular risk, functional influences like circadian immune activity may also affect vascular patency. Neutrophils, key mediators of ischemic injury, exhibit circadian oscillations in phenotype and function that could modulate collateral flow and stroke outcome. METHODS: We combined permanent and transient middle cerebral artery occlusion models in mice with flow cytometry, single-cell RNA sequencing, confocal microscopy, and laser speckle imaging to investigate time-of-day–dependent neutrophil mechanisms in stroke. Pharmacological (chloramidine, DNase-I) and genetic (Pad4 [peptidyl arginine deiminase 4] −/ − , Bmal1 [brain and muscle ARNT (aryl hydrocarbon receptor nuclear translocator)-like 1] Neu , Cxcr4 [C-X-C chemokine receptor type 4] Neu ) interventions were used to define how time-of-day regulation shapes neutrophil function, neutrophil extracellular traps (NETs) formation, and stroke severity. A cohort of 540 patients with ischemic stroke was analyzed for diurnal patterns of NET-related biomarkers and their association with collateral circulation and clinical outcomes. RESULTS: Infarct volume and neurological deficits exhibited clear circadian oscillations, with worse outcomes when stroke occurred during the murine inactive phase (Zeitgeber time 5) versus the active phase (Zeitgeber time 13). These fluctuations disappeared after neutrophil depletion or clock disruption. During the inactive phase, neutrophils displayed an activated, NET-prone phenotype, causing microvascular stalling and reduced collateral perfusion. Inhibiting NET formation pharmacologically or through Pad4 deletion restored perfusion and abolished time-of-day effects. In patients, neutrophil and NET-related biomarkers (MPO [myeloperoxidase], elastase, sCD40L [soluble CD40 ligand]) showed diurnal oscillations, peaking during the human inactive phase (evening/night), coinciding with reduced collateral flow and poorer outcomes. CONCLUSIONS: Time-of-day regulation of neutrophil function critically determines collateral perfusion and stroke severity. Neutrophil-driven NETosis during the inactive phase promotes microvascular obstruction and worsens outcomes. Targeting NET formation or timing therapy could enhance collateral efficacy and offer novel chronotherapeutic opportunities for stroke treatment.

23 November 2021 in Materials
Verified
Journal Article
Open access
PDF file
JMJuan Carlos Marín
Juan Carlos Marín
BBBlanca Díaz Benito
Blanca Díaz Benito
LMLuís Martins
Luís Martins
STSANDRA TRUJILLO
SANDRA TRUJILLO
LCLourdes Cordón
Lourdes Cordón
José Luis Gómez RibellesJosé Luis Gómez Ribelles
José Luis Gómez Ribelles
The development of three-dimensional environments to mimic the in vivo cellular response is a problem in the building of disease models. This study aimed to synthesize and validate three-dimensional support for culturing monoclonal plasma cells (mPCs) as a disease model for multiple myeloma. The three-dimensional environment is a biomimetic microgel formed by alginate microspheres and produced on a microfluidic device whose surface has been functionalized by a layer-by-layer process with components of the bone marrow’s extracellular matrix, which will interact with mPC. As a proof of concept, RPMI 8226 cell line cells were cultured in our 3D culture platform. We proved that hyaluronic acid significantly increased cell proliferation and corroborated its role in inducing resistance to dexamethasone. Despite collagen type I having no effect on proliferation, it generated significant resistance to dexamethasone. Additionally, it was evidenced that both biomolecules were unable to induce resistance to bortezomib. These results validate the functionalized microgels as a 3D culture system that emulates the interaction between tumoral cells and the bone marrow extracellular matrix. This 3D environment could be a valuable culture system to test antitumoral drugs efficiency in multiple myeloma.

13 January 2026 in Annals of Neurology
Verified
Journal Article
Open access
BBBlanca Díaz Benito
Blanca Díaz Benito
PCP. Calleja
P. Calleja
LAL. Alzamora
L. Alzamora
ARA. Ruiz‐García
A. Ruiz‐García
AMA. Martínez‐Salio
A. Martínez‐Salio
ILIgnacio Lizasoain
Ignacio Lizasoain
Objective: Immunothrombosis contributes to ischemic stroke pathophysiology through neutrophil extracellular trap (NET) formation, which promotes thrombus stabilization and microvascular dysfunction. DNase1 is the principal endonuclease responsible for NET degradation. The rs1053874 polymorphism in DNase1 gene influences enzymatic activity and protein stability in vitro, but its clinical relevance in ischemic stroke remains unexplored. We investigated whether this variant modulates systemic NET burden and impacts stroke‐related outcomes. Methods: We conducted a prospective observational cohort study including 492 patients with acute ischemic stroke. Genotyping of rs1053874 was performed via Sanger sequencing and categorized into AA versus GG + GA genotypes (dominant model). Clinical variables, NET biomarkers (elastase, myeloperoxidase [MPO], and dsDNA), DNAse1 activity, infarct volume, thrombectomy metrics, and survival were assessed. Multivariable regression and Cox proportional hazards models were used to explore associations between genotype and outcomes. Results: AA genotype carriers (7.9%) had a significantly lower burden of prior vascular events compared to GG + GA carriers. At admission, they exhibited higher DNAse1 activity, reduced levels of circulating NET markers (elastase, MPO, and dsDNA), and lower neutrophil and monocyte counts. Despite similar initial stroke severity, AA carriers required fewer thrombectomy passes and had significantly better early neurological recovery and smaller infarcts. In adjusted models, both the AA genotype and dyslipidemia were independently associated with improved long‐term survival. However, stratified analyses revealed the most robust survival benefit among AA carriers without dyslipidemia. No significant interaction was observed. Interpretation: DNase1 rs1053874 polymorphism influences NET‐related inflammation and is associated with improved vascular profile, procedural efficiency, and long‐term outcomes in ischemic stroke. These findings support the potential of DNase1 as a therapeutic and prognostic target in personalized stroke care. ANN NEUROL 2026;99:1210–1223

7 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
BBBlanca Díaz Benito
Blanca Díaz Benito
PCP Calleja
P Calleja
FOF Ostos
F Ostos
ARA Ruiz-García
A Ruiz-García
LAL Alzamora
L Alzamora
ILIgnacio Lizasoain
Ignacio Lizasoain
Background: Immunothrombosis is increasingly recognized in large-vessel-occlusion acute ischemic stroke (LVO-AIS), yet most biomarker studies infer thrombus biology from circulating neutrophil extracellular trap (NET) markers or from pre-defined thrombus subtypes. We prospectively studied 160 patients with anterior-circulation LVO-AIS treated with mechanical thrombectomy to determine whether intrathrombus NETosis markers identify thrombus phenotypes with distinct clinical trajectories, and whether plasma NETosis biomarkers reflect the molecular composition of thrombi. Methods: Thrombi underwent quantitative histopathology and immunohistochemistry for citrullinated histone H3 (CitH3), neutrophil elastase (NE) and CD61. Thrombi were analyzed without prior etiological or histological stratification, and intrathrombus markers were dichotomized at cohort medians (CitH3 6.62%, NE 3.95%, CD61 23.09%) to define internally standardized candidate phenotypes. Associations with thrombus composition, collateral circulation (Tan 2-3), 3-month functional independence (modified Rankin Scale 2 or less) and long-term mortality were assessed by correlation analyses and progressively adjusted multivariable models, with cross-compartment correlations corrected by the Benjamini-Hochberg false discovery rate (FDR). Results: Intrathrombus markers defined prognostically distinct phenotypes: CD61 tracked functional recovery, NE preserved collateral circulation and CitH3 long-term survival, each remaining significant after multivariable adjustment. Circulating NE, myeloperoxidase and leukocyte count instead tracked the macroscopic red-blood-cell-fibrin composition of retrieved thrombi. Cross-compartment concordance was limited: after FDR correction the only significant plasma-thrombus association was an inverse correlation between plasma cell-free DNA and intrathrombus NE, and no intrathrombus marker correlated positively with its circulating counterpart. Conclusions: Local immunothrombotic signatures therefore provide clinically relevant information not captured by plasma markers, and median-defined intrathrombus thresholds represent hypothesis-generating cutoffs for external validation and NET-targeted treatment stratification.